Applied Genetic Technologies (AGTC)

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

AGTC stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors


15 May 22
12 Aug 22
30 Jun 23
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jun 21 Jun 20 Jun 19 Jun 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 67.85M 67.85M 67.85M 67.85M 67.85M 67.85M
Cash burn (monthly) 1.64M 1.81M 4.53M 5.19M 4.67M 5.08M
Cash used (since last report) 7.25M 7.99M 20.01M 22.93M 20.62M 22.44M
Cash remaining 60.6M 59.86M 47.84M 44.92M 47.23M 45.41M
Runway (months of cash) 36.9 33.1 10.6 8.7 10.1 8.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 22 Stephen W Potter Common Stock Sell Dispose S No No 0.7745 8,070 6.25K 55,883
27 May 22 Gerald Anthony Reynolds Common Stock Sell Dispose S No No 0.8452 3,994 3.38K 21,006
18 Feb 22 Susan B. Washer Common Stock Sell Dispose S No No 2.18 9,950 21.69K 143,021
18 Feb 22 Susan B. Washer Common Stock Option exercise Acquire M No No 0.35 120,686 42.24K 152,971
18 Feb 22 Susan B. Washer Stock Option Common Stock Option exercise Dispose M No No 0.35 120,686 42.24K 0
13 Dec 21 Hope DOyley-Gay Stock Option Common Stock Grant Acquire A No No 2.02 180,000 363.6K 180,000
36.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 59 60 -1.7%
Opened positions 10 9 +11.1%
Closed positions 11 18 -38.9%
Increased positions 15 12 +25.0%
Reduced positions 15 20 -25.0%
13F shares Current Prev Q Change
Total value 27.29M 70.69M -61.4%
Total shares 18.46M 17.13M +7.8%
Total puts 49.5K 89K -44.4%
Total calls 50.4K 48.8K +3.3%
Total put/call ratio 1.0 1.8 -46.1%
Largest owners Shares Value Change
Cantor Fitzgerald, L. P. 2.36M $2.52M NEW
Vanguard 1.98M $2.12M +14.4%
Millennium Management 1.65M $1.76M +7.5%
Portolan Capital Management 1.61M $1.72M +18.0%
Interwest Partners Viii 1.4M $2.67M 0.0%
Interwest Venture Management 1.4M $1.5M 0.0%
Intersouth Partners Vi 1.21M $4.97M 0.0%
BLK Blackrock 1.12M $1.2M +1.1%
Sabby Management 970.06K $1.04M NEW
Integrated Core Strategies 717.36K $2.93M 0.0%
Largest transactions Shares Bought/sold Change
Cantor Fitzgerald, L. P. 2.36M +2.36M NEW
Empery Asset Management 100K -1.87M -94.9%
Sabby Management 970.06K +970.06K NEW
Altrinsic Global Advisors 0 -376.9K EXIT
Vanguard 1.98M +248.82K +14.4%
Portolan Capital Management 1.61M +244.9K +18.0%
MS Morgan Stanley 43.04K -209.83K -83.0%
Two Sigma Advisers 117.73K -172.5K -59.4%
Ci Investments 161.8K +161.8K NEW
Assenagon Asset Management 277.66K -152.9K -35.5%

Financial report summary

Management Discussion
  • During the years ended June 30, 2021 and 2020, we recognized total revenue of $0.5 million and $2.5 million, respectively.
  • Effective April 13, 2021, we entered into a license agreement with a third party whereby we provided nonexclusive rights to our proprietary cone-specific promoter technology for use in the development of two non-competing products. In connection with this agreement, we recognized $0.5 million of license fee revenue during the year ended June 30, 2021.
  • During December 2019, Bionic Sight met a milestone related to clearance of filing of an Investigational New Drug application under its collaboration agreement with us and, as a result, we recognized $2.2 million of non-cash collaboration revenue during the year ended June 30, 2020 in connection with in-kind contributions made since inception of the Bionic Sight collaboration agreement. During the year ended June 30, 2020, we also recorded $0.2 million and $0.1 million of grant revenue and other milestone revenue, respectively.

Content analysis

H.S. freshman Avg
New words: afforded, agreed, aninitial, appeal, approach, architectural, ARVO, assay, bid, broader, budget, canhave, chart, clear, coefficient, combat, comply, consecutive, cure, dB, deemed, delisted, delisting, Demographic, diminished, drove, earlier, equivalent, escrow, fact, fewer, fora, fortify, inflation, intent, intraocular, invoice, invoiced, Journal, larger, listing, loglux, meaningful, Nasdaq, paid, panel, perimeter, pressure, prime, proposed, rapidly, regain, reiterated, repeatability, Snellen, Street, substantive, surgical, theofficer, toanofficer, unevaluable, Wall
Removed: advancement, biologic, committee, criterion, decibel, demonstrate, discretion, enable, launch, November, profile, senior, strategy, twenty


Recombinant Aav Production In Mammalian Cells
4 Nov 21
The present invention includes methods and compositions for the production of high titer recombinant Adeno-Associated Virus (rAAV) in a variety of mammalian cells.
Codon Optimized Nucleic Acid Encoding a Retinitis Pigmentosa Gtpase Regulator (RPGR)
10 Jun 21
This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein.
Promoters, Expression Cassettes, Vectors, Kits, and Methods for the Treatment of Achromatopsia and Other Diseases
27 May 21
The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
Adeno-associated Virus (Aav) Systems for Treatment of Progranulin Associated Neurodegenerative Diseases or Disorders
20 May 21
The disclosure provides, in part, optimally-modified progranulin (PGRN) cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for neurodegenerative disorders characterized by cognitive disruption, behavioral impairment, and deficient lysosomal storage, including familial frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), neuronal ceroid lipofuscinosis (NCL), or Alzheimer's disease (AD).
Triple Function Adeno-associated Virus (Aav)vectors for the Treatment of C9ORF72 Associated Diseases
20 May 21
The present disclosure provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of C9ORF72 associated diseases, including ALS and FTD.